```
=> d his

     (FILE 'HOME' ENTERED AT 11:43:22 ON 21 MAR 2008)

     FILE 'CAPLUS' ENTERED AT 11:43:32 ON 21 MAR 2008
                E US2005-550760/APPS
L1            1 S E3
                SEL L1 RN

     FILE 'REGISTRY' ENTERED AT 11:44:52 ON 21 MAR 2008
L2           39 S E1-E39

     FILE 'STNGUIDE' ENTERED AT 11:46:11 ON 21 MAR 2008

     FILE 'REGISTRY' ENTERED AT 12:00:33 ON 21 MAR 2008
                E "1H-IMIDAZOLE-5-CARBOXYLIC ACID, 2-BUTYL-4-CHLORO-1-((2'-(2H-
                E "1H-IMIDAZOLE-5-CARBOXYLIC ACID, 2-BUTYL-4-(PENTAFLUOROETHYL)
                E "3H-IMIDAZO(4,5-B)PYRIDINE, 2-ETHYL-5,7-DIMETHYL-3-((2'-(2H-T
                E "5-PYRIMIDINECARBOXYLIC ACID, 4-(BUTYL((2'-(2H-TETRAZOL-5-YL)
                E "1H-TETRAZOLE, 5-(4'-((3,5-DIBUTYL-1H-1,2,4-TRIAZOL-1-YL)METH
                E "2H-IMIDAZOL-2-ONE, 1,4-DIBUTYL-1,3-DIHYDRO-3-((2'-(1H-TETRAZ
                E "QUINOLINE, 2-ETHYL-4-((2'-(2H-TETRAZOL-5-YL)(1,1'-BIPHENYL)-
                E "QUINOLINE, 2-ETHYL-5,6,7,8-TETRAHYDRO-4-((2'-(2H-TETRAZOL-5-
L3            1 S "1H-IMIDAZOLE-5-CARBOXYLIC ACID, 2-BUTYL-4-CHLORO-1-((2'-(2H-
L4            1 S "1H-IMIDAZOLE-5-CARBOXYLIC ACID, 2-BUTYL-4-(PENTAFLUOROETHYL)
L5            1 S "3H-IMIDAZO(4,5-B)PYRIDINE, 2-ETHYL-5,7-DIMETHYL-3-((2'-(2H-T
L6            1 S "5-PYRIMIDINECARBOXYLIC ACID, 4-(BUTYL((2'-(2H-TETRAZOL-5-YL)
L7            1 S "1H-TETRAZOLE, 5-(4'-((3,5-DIBUTYL-1H-1,2,4-TRIAZOL-1-YL)METH
L8            1 S "2H-IMIDAZOL-2-ONE, 1,4-DIBUTYL-1,3-DIHYDRO-3-((2'-(1H-TETRAZ
L9            1 S "QUINOLINE, 2-ETHYL-4-((2'-(2H-TETRAZOL-5-YL)(1,1'-BIPHENYL)-
L10           1 S "QUINOLINE, 2-ETHYL-5,6,7,8-TETRAHYDRO-4-((2'-(2H-TETRAZOL-5-

     FILE 'CAPLUS, USPATFULL, USPATOLD, USPAT2' ENTERED AT 12:05:44 ON 21 MAR
     2008
L11         520 S L3-L10
L12       38368 S (METABOLIC SYNDROME X) OR (SYNDROME X) OR (INSULIN RESISTANCE
L13          12 S L11 AND L12
L14           4 S L13 AND PY<2004
                SAVE TEMP ALL A10550760/L
```

=> d ibib abs hitstr 1-4

L14 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2003:701277 CAPLUS <<LOGINID::20080321>>
DOCUMENT NUMBER: 140:104847
TITLE: Effects of angiotensin II receptor antagonists on insulin resistance syndrome and leptin in sucrose-fed spontaneously hypertensive rats
AUTHOR(S): Umeda, Mamoru; Kanda, Tsugiyasu; Murakami, Masami
CORPORATE SOURCE: Department of Laboratory Medicine Gunma University School of Medicine, Maebashi, Japan
SOURCE: Hypertension Research (2003), 26(6), 485-492
CODEN: HRESE4; ISSN: 0916-9636
PUBLISHER: Japanese Society of Hypertension
DOCUMENT TYPE: Journal
LANGUAGE: English
AB In order to investigate the usefulness of angiotensin II type 1 receptor (AT1) antagonists (ARA) in the treatment of hypertension with insulin resistance syndrome, we studied the effects of a high dose sucrose diet and ARA on insulin sensitivity, plasma lipids, and leptin in spontaneous hypertensive rats (SHR) and WistarKyoto rats (WKY). SHR and WKY were divided into three groups and treated for 12 wk: those fed a standard chow, those given a sucrose-rich chow or those given a sucrose-rich chow and ARA. While in SHR the weight of both s.c. and mesenteric adipose tissue was greater in the sucrose-rich chow fed animals than in the standard chow fed animals, ARA treatment significantly decreased the wts. of both s.c. and mesenteric adipose tissue. ARA treatment decreased free fatty acid and triglyceride in SHR, and increased high d. lipoprotein cholesterol in SHR and WKY. Homeostasis model assessment-insulin resistance (HOMA-IR) index, plasma levels of leptin, and leptin mRNA in mesenteric adipose tissue were significantly greater in the sucrose-rich chow fed animals than in the standard chow fed animals, and significantly lower in the ARA-treated sucrose-rich chow fed animals than in the sucrose-rich chow fed animals in both SHR and WKY. ARA improved insulin resistance, and reduced plasma leptin and leptin mRNA in adipose tissue. These results suggest that the improvement of insulin resistance by ARA may be attributed, at least in part, to the reduction of adipose tissue weight It is concluded that ARA is useful in the treatment of patients with hypertension and concomitant insulin resistance syndrome.
IT 133240-46-7, L-158809
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(effects of angiotensin II receptor antagonists on insulin resistance syndrome and leptin in sucrose-fed spontaneously hypertensive rats)
RN 133240-46-7 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine, 2-ethyl-5,7-dimethyl-3-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]- (CA INDEX NAME)



REFERENCE COUNT: 43 THERE ARE 43 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 2 OF 4 USPATFULL on STN

ACCESSION NUMBER:	2002:214313 USPATFULL <<LOGINID::20080321>>
TITLE:	Use of an angiotensin II receptor antagonist for the preparation of drugs to increase the survival rate of renal transplant patients
INVENTOR(S):	Remuzzi, Giuseppe, Bergamo, ITALY
PATENT ASSIGNEE(S):	MERCK SHARP & DOHME (Italia) S.p.A., Roma, ITALY (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002115702	A1	20020822	<--
	US 6576652	B2	20030610	
APPLICATION INFO.:	US 2002-76396	A1	20020219 (10)	
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2000-509791, filed on 30 Mar 2000, PENDING			

	NUMBER	DATE
PRIORITY INFORMATION:	IT 1997-RM586	19970930

DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	BROWDY AND NEIMARK, P.L.L.C., SUTIE 300, 624 NINTH STREET, N.W., WASHINGTON, DC, 20001-5303
NUMBER OF CLAIMS:	21
EXEMPLARY CLAIM:	1
LINE COUNT:	2068

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to the use, for the preparation of drugs to increase the survival rate of transplant patients, including renal and heart transplant patients, of a therapeutically effective amount of an angiotension II receptor antagonist compound, such as the class of substituted imidazoles represented by formula (I) and in particular by losartan potassium, 2-butyl-4-chloro-[(2'-tetrazol-5-yl)biphenyl-4-il]methyl]-5-(hydroxymethyl)imidazole potassium salt.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 124750-92-1P
(preparation of drugs to increase the survival rate of renal transplant patients)

RN 124750-92-1 USPATFULL

CN 1H-Imidazole-5-carboxylic acid, 2-butyl-4-chloro-1-[[2'-(2H-tetrazol-5-

yl)[1,1'-biphenyl]-4-yl]methyl]- (CA INDEX NAME)



L14 ANSWER 3 OF 4 USPATFULL on STN

ACCESSION NUMBER:	1999:121402 USPATFULL <<LOGINID::20080321>>
TITLE:	Insulin sensitivity with angiotensin II receptor blocking imidazoles
INVENTOR(S):	Eide, Ivar K., P.O. Box 2000, Rahway, NJ, United States 07065 Moan, Andreas, P.O. Box 2000, Rahway, NJ, United States 07065 Kjeldsen, Sverre E., P.O. Box 2000, Rahway, NJ, United States 07065

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5962500		19991005	<--
APPLICATION INFO.:	US 1998-128138		19980803 (9)	

RELATED APPLN. INFO.: Continuation of Ser. No. US 1997-958236, filed on 27 Oct 1997, now abandoned which is a continuation of Ser. No. US 1996-775696, filed on 31 Dec 1996, now abandoned which is a continuation of Ser. No. US 1995-406620, filed on 20 Mar 1995, now abandoned

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1994-6573	19940331

DOCUMENT TYPE:	Utility
FILE SEGMENT:	Granted
PRIMARY EXAMINER:	Cooney, Jr., John M.
LEGAL REPRESENTATIVE:	Camara, Valerie J., Daniel, Mark R.
NUMBER OF CLAIMS:	7
EXEMPLARY CLAIM:	1
LINE COUNT:	1510

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to a novel method of using an Angiotensin II antagonist for the improvement of insulin sensitivity alone or in conjunction with the treatment of hypertension. Angiotensin II antagonists such as the class of substituted imidazoles represented by formula I: ##STR1## and specifically by Losartan, 2-butyl-4-chloro-1-[(2'-tetrazol-5-yl)biphenyl-4-yl]methyl]-5-(hydroxymethyl)imidazole potassium salt.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 124750-92-1P
(improvement of insulin sensitivity with angiotensin II receptor-blocking imidazoles)
RN 124750-92-1 USPATFULL
CN 1H-Imidazole-5-carboxylic acid, 2-butyl-4-chloro-1-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]- (CA INDEX NAME)



L14 ANSWER 4 OF 4 USPAT2 on STN
ACCESSION NUMBER: 2002:214313 USPAT2 <<LOGINID::20080321>>
TITLE: Use of an angiotensin II receptor antagonist for the preparation of drugs to increase the survival rate of renal transplant patients
INVENTOR(S): Remuzzi, Giuseppe, Bergamo, ITALY
PATENT ASSIGNEE(S): Merck Sharp & Dohme (Italia) S.p.A., Rome, ITALY (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6576652	B2	20030610	<--
APPLICATION INFO.:	US 2002-76396		20020219 (10)	

RELATED APPLN. INFO.: Continuation of Ser. No. US 2000-509791, filed on 30 Mar 2000, now abandoned

	NUMBER	DATE
PRIORITY INFORMATION:	IT 1997-RM586	19970930

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Weddington, Kevin E.
LEGAL REPRESENTATIVE: Browdy & Neimark PLLC
NUMBER OF CLAIMS: 21
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 2179
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to the use, for the preparation of drugs to increase the survival rate of transplant patients, including renal and heart transplant patients, of a therapeutically effective amount of an angiotension II receptor antagonist compound, such as the class of substituted imidazoles represented by formula (I) and in particular by losartan potassium, 2-butyl-4-chloro-[(2'-tetrazol-5-yl)biphenyl-4-

il]methyl]-5-(hydroxymethyl)imidazole potassium salt.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 124750-92-1P
(preparation of drugs to increase the survival rate of renal transplant patients)
RN 124750-92-1 USPAT2
CN 1H-Imidazole-5-carboxylic acid, 2-butyl-4-chloro-1-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]- (CA INDEX NAME)



=> d l3

L3 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2008 ACS on STN
RN 124750-92-1 REGISTRY
ED Entered STN: 12 Jan 1990
CN 1H-Imidazole-5-carboxylic acid, 2-butyl-4-chloro-1-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]- (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 1H-Imidazole-5-carboxylic acid, 2-butyl-4-chloro-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]- (9CI)
OTHER NAMES:
CN E 3174
CN EXP 3174
MF C22 H21 Cl N6 O2
CI COM
SR CA
LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOSIS, BIOTECHNO, CA, CAPLUS, CASREACT, CHEMCATS, DDFU, DRUGU, EMBASE, IMSRESEARCH, IPA, MEDLINE, RTECS*, SYNTHLINE, TOXCENTER, USPAT2, USPATFULL
(*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

260 REFERENCES IN FILE CA (1907 TO DATE)
7 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
260 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> d l4

L4 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2008 ACS on STN
RN 124750-94-3 REGISTRY
ED Entered STN: 12 Jan 1990
CN 1H-Imidazole-5-carboxylic acid, 2-butyl-4-(pentafluoroethyl)-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]- (9CI) (CA INDEX NAME)
MF C24 H21 F5 N6 O2
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

5 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
5 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> d l5

L5 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2008 ACS on STN
RN 133240-46-7 REGISTRY
ED Entered STN: 12 Apr 1991
CN 3H-Imidazo[4,5-b]pyridine, 2-ethyl-5,7-dimethyl-3-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]- (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 3H-Imidazo[4,5-b]pyridine, 2-ethyl-5,7-dimethyl-3-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]- (9CI)
OTHER NAMES:
CN L 158809
MF C24 H23 N7
SR CA
LC STN Files: ADISINSIGHT, BEILSTEIN*, BIOSIS, BIOTECHNO, CA, CAPLUS, CASREACT, DDFU, DRUGU, EMBASE, IPA, PHAR, RTECS*, TOXCENTER, USPAT2, USPATFULL
(*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

173 REFERENCES IN FILE CA (1907 TO DATE)
6 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

173 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> d l6

L6 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2008 ACS on STN
RN 141872-46-0 REGISTRY
ED Entered STN: 19 Jun 1992
CN 5-Pyrimidinecarboxylic acid, 4-[butyl[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]amino]- (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 5-Pyrimidinecarboxylic acid, 4-[butyl[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]amino]- (9CI)
OTHER NAMES:
CN Abbott 81282
MF C23 H23 N7 O2
CI COM
SR CA
LC STN Files: BEILSTEIN*, BIOSIS, CA, CAPLUS, CASREACT, CHEMCATS, IMSRESEARCH, MEDLINE, PROUSDDR, TOXCENTER, USPATFULL
(*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

12 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
12 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> d l7

L7 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2008 ACS on STN
RN 140120-42-9 REGISTRY
ED Entered STN: 03 Apr 1992
CN 1H-Tetrazole, 5-[4'-[(3,5-dibutyl-1H-1,2,4-triazol-1-yl)methyl][1,1'-biphenyl]-2-yl]- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN SC 50560
MF C24 H29 N7
SR CA

LC STN Files: ADISINSIGHT, CA, CAPLUS, PHAR, PROUSDDR, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

18 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
18 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> d l8

L8 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2008 ACS on STN
RN 141386-89-2 REGISTRY
ED Entered STN: 15 May 1992
CN 2H-Imidazol-2-one, 1,4-dibutyl-1,3-dihydro-3-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN SC 51895
MF C25 H30 N6 O
SR CA
LC STN Files: ADISINSIGHT, CA, CAPLUS, PHAR, PROUSDDR, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

12 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
12 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> d l9

L9 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2008 ACS on STN
RN 143494-72-8 REGISTRY
ED Entered STN: 18 Sep 1992
CN Quinoline, 2-ethyl-4-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methoxy]- (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Quinoline, 2-ethyl-4-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methoxy]- (9CI)
OTHER NAMES:
CN D 8731
CN ICI-D 8731
MF C25 H21 N5 O
CI COM
SR CA
LC STN Files: CA, CAPLUS, CASREACT, MEDLINE, TOXCENTER, USPAT2, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

35 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
35 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> d l10

L10 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2008 ACS on STN
RN 138620-04-9 REGISTRY
ED Entered STN: 31 Jan 1992
CN Quinoline, 2-ethyl-5,6,7,8-tetrahydro-4-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methoxy]- (CA INDEX NAME)

OTHER CA INDEX NAMES:
CN Quinoline, 2-ethyl-5,6,7,8-tetrahydro-4-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methoxy]- (9CI)
OTHER NAMES:
CN ICI-D 6888
CN ZD 6888
MF C25 H25 N5 O
CI COM
SR CA
LC STN Files: ADISINSIGHT, BIOSIS, CA, CAPLUS, PHAR, PROUSDDR, TOXCENTER, USPAT2, USPATFULL



L1 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:857382 CAPLUS <<LOGINID::20080321>>
DOCUMENT NUMBER: 141:325747
TITLE: Use of an angiotensin II type 1 receptor antagonist for the treatment or prevention of metabolic syndrome
INVENTOR(S): Ljunggren, Anders; Svensson, Anders
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.
SOURCE: PCT Int. Appl., 30 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004087136	A1	20041014	WO 2004-SE505	20040331
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004226517	A1	20041014	AU 2004-226517	20040331
AU 2004226517	B2	20080124		
CA 2520960	A1	20041014	CA 2004-2520960	20040331
EP 1613309	A1	20060111	EP 2004-724927	20040331
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
BR 2004008979	A	20060404	BR 2004-8979	20040331
CN 1771033	A	20060510	CN 2004-80009394	20040331
JP 2006522115	T	20060928	JP 2006-507997	20040331
NO 2005004370	A	20051031	NO 2005-4370	20050921
US 2006194856	A1	20060831	US 2005-550760	20050927 <--
PRIORITY APPLN. INFO.:			SE 2003-988 A	20030403
			WO 2004-SE505 A	20040331

OTHER SOURCE(S): MARPAT 141:325747
REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT